150’000 CHF for a breathing stimulation device to speed-up recovery of ventilated patients – a need in the COVID-19 pandemy.
31.03.2020
In crisis times, when startups need it the most, Venture Kick continues to support Swiss startups. The board is excited to give one of the joker kicks to STIMIT developing medical devices for patients lacking natural breathing function, a crucial need in times of Corona. The Nidau-based company was awarded CHF 150,000.
 |
 |
 Left to right: Peter Frei, Board Member - Olivier Mülller, co-founder - Ronja Brühn, CEO and co-founder - Prof. Hans Pargger, Customer Perspective
|
|
Beginning of 2020 ’Venture Kick Life Science‘ was launched as a special track for biotech and medtech startups, both key assets of our country. They especially need support during this corona crisis. STIMIT is the first startup benefiting from this pilot project support. It will help patient hospitalized for respiratory insufficiency to recover faster via diaphragm stimulation.
Severe cases of COVID-19 require intensive care and mechanical ventilation. The average duration of ventilation in severe hospitalized COVID-19 patients is 12 days. Weaning (the process of liberation from mechanical ventilation) is going to be difficult, takes time and ties up staff resources. COVID19 is one of the most severe pandemics challenging intensive care resources to bring down mortality.
STIMIT founder Ronja Bruhn is developing therapy and medical device to empower patients in intensive care to breathe. The startup’s technology can non-invasively activate the body's own breathing function. The therapy goal is to maintain breathing muscle function during ventilation, to minimize life-threatening damage to the lungs from mechanical ventilation, and shorten the duration of ventilation for intensive care patients.
"Currently we focus on bringing our breathing stimulation device to the market and we must not lose time" says founder Ronja Bruhn. "Venture Kick’s additional support will accelerate STIMIT in bringing this novel therapy and device to market. Our goal is to improve outcomes in ventilated patients and treat more patients in less time."
Severe cases of COVID-19 require intensive care and mechanical ventilation. The average duration of ventilation in severe hospitalized COVID-19 patients is 12 days. Weaning (the process of liberation from mechanical ventilation) is going to be difficult, takes time and ties up staff resources. COVID19 is one of the most severe pandemics challenging intensive care resources to bring down mortality.
STIMIT founder Ronja Bruhn is developing therapy and medical device to empower patients in intensive care to breathe. The startup’s technology can non-invasively activate the body's own breathing function. The therapy goal is to maintain breathing muscle function during ventilation, to minimize life-threatening damage to the lungs from mechanical ventilation, and shorten the duration of ventilation for intensive care patients.
"Currently we focus on bringing our breathing stimulation device to the market and we must not lose time" says founder Ronja Bruhn. "Venture Kick’s additional support will accelerate STIMIT in bringing this novel therapy and device to market. Our goal is to improve outcomes in ventilated patients and treat more patients in less time."